Press Release History - 2010

  • 3 Dec 2010
    ThromboGenics successfully completes private placement raising €56 million
  • 2 Dec 2010
    ThromboGenics Announces a Private Placement of New Ordinary Shares
  • 2 Dec 2010
    ThromboGenics Successfully Completes Private Placement Raising €56 million
  • 5 Nov 2010
    Transparency Notification
  • 5 Nov 2010
    ThromboGenics NV – Business Update
  • 29 Oct 2010
    ThromboGenics receives transparency notification
  • 26 Oct 2010
    ThromboGenics Raises € 2.8 Million from the Exercise of Warrants
  • 30 Sep 2010
    ThromboGenics Signs Deal with MSD for Long-Term Commercial Supply of Microplasmin
  • 15 Sep 2010
    Transparency Declaration
  • 14 Sep 2010
    Transparency Information
  • 6 Sep 2010
    ThromboGenics Presents Positive Pooled Results from the MIVITRUST Phase III Program, Confirming Microplasmin’s Potential to Transform the Treatment of Retinal Disorders
  • 1 Sep 2010
    Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial
  • 26 Aug 2010
    ThromboGenics NV Announces 2010 First Half Results
  • 15 Jul 2010
    ThromboGenics Announces Publication of Positive Microplasmin Phase II Data in the Journal Retina
  • 9 Jul 2010
    Positive Results from Phase II VTE Prophylaxis Study with TB-402 (Anti-Factor VIII) Presented at the 21st International Congress
  • 1 Jul 2010
    ThromboGenics to Present Results of Second Phase III Trial of Microplasmin at the 28th Annual Meeting of the American Society of Retina Specialists (ASRS) and the 10th EURETINA Congress
  • 7 Jun 2010
    ThromboGenics Presents New Exciting Microplasmin Phase III Data at the World Ophthalmology Congress (WOC) in Berlin
  • 17 May 2010
    ThromboGenics and BioInvent to Receive €10 Million Milestone as Partner Roche Begins New Clinical Study with TB-403
  • 11 May 2010
    ThromboGenics NV – Business Update
  • 6 May 2010
    ThromboGenics and BioInvent Announce Positive Topline Results from Phase II VTE Prophylaxis Study with Anti-Factor VIII (TB-402)
  • 20 Apr 2010
    ThromboGenics Announces that Microplasmin Meets Primary Endpoint in Phase III Trial for the Non-Surgical Treatment of Symptomatic Vitreomacular Adhesion (VMA)
  • 25 Mar 2010
    ThromboGenics Raises € 0.6 Million from the Exercise of Warrants
  • 12 Mar 2010
    ThromboGenics Announces Business Update and 2009 Full Year Results
  • 9 Feb 2010
    ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology